Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Indian J Hematol Blood Transfus ; 31(2): 169-73, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25825554

ABSTRACT

Acute megakaryoblastic leukemia is a rare subtype of acute myeloid leukemia with a characteristic morphologic and immunophenotypic profile. It has to be distinguished from other subtypes of acute myeloid leukemia as well as acute myeloid leukemia with t (1; 22) (p13;q13) and acute megakaryoblastic leukemia in Down Syndrome because of its poor prognosis. We studied ten cases diagnosed over a period of 2 years (from July 2011 to June 2013). All the ten cases were in the pediatric age group ranging from 4 months to 2 years. On morphology, pointers to the diagnosis were clustering of blasts, presence of cytoplasmic blebs and platelet budding. An additional interesting morphological feature observed in our study was nuclear blebs which were seen in nine cases. Diagnosis was confirmed in all cases by positive immunostaining for CD61. Two of the cases had an extremely rare clinical presentation as granulocytic sarcoma. Although rare, acute megakaryoblastic leukemia should be kept in mind especially in leukemia in infants.

2.
Indian Pediatr ; 36(1): 29-36, 1999 Jan.
Article in English | MEDLINE | ID: mdl-10709120

ABSTRACT

OBJECTIVE: To study the clinical profile and outcome of langerhans cell histiocytosis in children upto 2 years of life. DESIGN: Retrospective analysis. METHODS: Medical records of Children upto 2 years of age with a diagnosis of langerhans cell histiocytosis (LCH) were analyzed. Their clinical pattern, treatment modalities and outcome were studied. The patients Were categorized into 2 groups according to their clinical presentation: (i) Subject without organ dysfunction; and (ii) cases with organ dysfunction. Treatment considered of surgical intervention, radiotherapy, chemotherapy or combination of all these modalities depending upto the extent of disease. RESULTS: There were 20 children upto 2 years of age with histiocytosis during the 12 year period (January 1983 - December 1994). The median age at diagnosis was 18 months (range 52 days - 24 months). Of the twenty patients,13 patients didn't have organ dysfunction and 7 had organ dysfunction. Out of the 13 children without organ dysfunction eleven patients received treatment and all of them are alive free of disease with a median follow up of 62 months. But all children with organ dysfunction succumbed to disease within a few weeks. CONCLUSION: Children under 2 years of age with localised and or multifocal LCH without organ dysfunction have a good prognosis and they should not be exposed to aggressive form of treatment. All children with organ dysfunction require multi-agent chemotherapy.


Subject(s)
Histiocytosis, Langerhans-Cell/physiopathology , Age Factors , Antineoplastic Agents, Phytogenic/therapeutic use , Bone Marrow Diseases/physiopathology , Bone Marrow Diseases/therapy , Child, Preschool , Combined Modality Therapy , Cyclophosphamide/therapeutic use , Disease-Free Survival , Female , Follow-Up Studies , Glucocorticoids/therapeutic use , Histiocytosis, Langerhans-Cell/drug therapy , Histiocytosis, Langerhans-Cell/therapy , Humans , Immunosuppressive Agents/therapeutic use , Infant , Liver Diseases/physiopathology , Liver Diseases/therapy , Lung Diseases/physiopathology , Lung Diseases/therapy , Male , Prednisolone/therapeutic use , Prognosis , Recurrence , Remission Induction , Retrospective Studies , Survival Rate , Treatment Outcome , Vinblastine/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...